Skip to main content

Table 4 Treatment with IgG by site of care

From: Growth in diagnosis and treatment of primary immunodeficiency within the global Jeffrey Modell Centers Network

 

2021

2018

2013

% change (%)

IVIG—clinic

 US

3604

3299

2572

40.1

 INT’L

15,385

9296

6285

144.8

 Global

18,989

12,595

8857

114.4

IVIG—home

 US

2449

2381

2423

1.1

 INT’L

895

842

418

114.1

 Global

3344

3223

4298

− 22.2

SCIG

 US

3822

2881

1631

134.3

 INT’L

9759

4778

2667

265.9

 Global

13,581

7659

2841

378.0

Total, including “other”

 US

9984

8721

7315

36.5

 INT’L

26,186

15,246

9910

164.2

 Global

36,170

23,967

17,225

110.0

  1. The number of patients reported to receive immunoglobulin therapy (IgG) intravenously in the clinic and at home, subcutaneously, and by other treatment modalities in 2021, 2018, and 2013